Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$1.6B
59M shares
52-week range
$15.30 – $30.00
85% from low
Sector
SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Exchange
NASDAQ
CS
Kestra Medical Technologies Ltd is a commercial-stage wearable medical device and digital healthcare company focused on connected monitoring, therapeutic intervention, and data-driven clinical insights for cardiovascular disease. It has developed and is commercializing the Cardiac Recovery System platform, an integrated cardiac recovery ecosystem designed to support patients at elevated risk of sudden cardiac arrest (SCA) during vulnerable periods of recovery. The platform is anchored by the ASSURE Wearable Cardioverter Defibrillator (WCD), which continuously monitors patient heart rhythms and automatically delivers defibrillation therapy when life-threatening ventricular arrhythmias are detected. The platform also includes digital patient engagement and clinical workflow solutions.
www.kestramedical.comNo one on the platform currently holds KMTS.
No tracked institution reports a position in KMTS as of their last filing.
No one on the platform has traded KMTS yet.
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
$KMTS JP Morgan initiates coverage with overweight rating JP Morgan initiates coverage with PT $30
View on StockTwits ↗https://www.marketbeat.com/earnings/reports/2026-7-14-kestra-medical-technologies-ltd-stock/ $KMTS Kestra Medical Technologies Earnings Tr
View on StockTwits ↗$KMTS woof…these analysts not liking the Rx guide for FY27… Gonna have the stock down. Nobody likes messy.
View on StockTwits ↗$KMTS Q4 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.67 up 69.68% YoY • Reported revenue of $28.64M up 66.18% YoY • Kestra Medical Technologies expects revenue of $137 million in fiscal year 2027, which would represent growth of 44% compared to the revenue reported for the fiscal year ended April 30, 2026.
View on StockTwits ↗$KMTS meh…declining magnitude of beat and bigger than expected profit losses. Modest guide ahead is non-event given insanity valuation and PE still looking to dump ~60% of the outstanding stock. Still only worth ~$5. 👎 $XLV $IHI $IWM $XBI
View on StockTwits ↗Fundamental analysis of $KMTS (KESTRA MEDICAL TECHNOLOGIES, LTD.) based on financial data and reported results. #KMTS
View on StockTwits ↗$KMTS Very shortable at anything above $20. Critically wounded stock. With 58.5M shares and mkt cap of 1.17B, this is an extreme bubble valuation (Check multiples). -Revenue growth is quickly slowing QOQ. Market is niche and tough to displace legacy competitors. -Operating expenses are skyrocketing, operating losses are deeper, and cash burn is unsustainable. -Cash is quickly dwindling; they need to dilute again before any breakeven. -Many millions of vested options are in the money = dilution. -Expensive debt with hefty interest costs. -Short interest is rapidly rising. -New IPO and insiders will be selling soon.
View on StockTwits ↗$KMTS Q3 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.61 up 51.20% YoY • Reported revenue of $24.55M up 62.70% YoY • Kestra Medical Technologies Ltd. increased its FY26 revenue guidance to $93M, representing 55% growth compared to FY25, an increase from prior guidance of $91M and initial guidance of $85M.
View on StockTwits ↗$KMTS Stage 1b(2) Double Bottom pattern with a pivot @ $28.84.
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2027 | $137M | +47.4% | $-2.30 | $-2.34–$-2.25 | — | 4 |
| 2028 | $194M | +41.3% | $-2.05 | $-2.09–$-2.00 | — | 4 |
| 2029 | $244M | +26.0% | $-1.84 | $-1.87–$-1.81 | — | 2 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 1 of the last 5 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-07-14 | $-0.59 | $-0.67 | -13.6% |
| 2026-03-17 | $-0.60 | $-0.61 | -1.7% |
| 2025-12-11 | $-0.59 | $-0.62 | -4.4% |
| 2025-09-11 | $-0.66 | $-0.46 | +30.3% |
| 2025-04-14 | $-0.60 | $-1.25 | -107.2% |
| $2.6B |
| — |
| NVCRNovocure Ltd | $17.38 | -1.19% | $2.0B | — |
| PGENPrecigen, Inc. | $6.49 | -5.26% | $2.3B | — |
Source: Financial Modeling Prep · peers by sector/industry